CARREL MICHAEL H
Known title: DirectorCIK: 0001230584
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Transaction History
| ATRC | ▼ Sell | Gift | 4,000 | $0 | 7/30/2026 | View on chart |
| ATRC | ▼ Sell | Gift | 700 | $0 | 7/30/2026 | View on chart |
| INSP | ▲ Buy | Grant | 5,631 | $0 | 7/20/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 636 | $15K | 6/30/2026 | View on chart |
| ATRC | ▼ Sell | Gift | 5,000 | $0 | 3/6/2026 | View on chart |
| ATRC | ▼ Sell | Gift | 1,000 | $0 | 3/6/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 68,618 | $0 | 3/1/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 101,280 | $0 | 3/1/2026 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 72,777 | $2.3M | 3/1/2026 | View on chart |
| ATRC | ▼ Sell | Gift | 4,000 | $0 | 12/10/2025 | View on chart |
| ATRC | ▼ Sell | Gift | 6,000 | $0 | 11/13/2025 | View on chart |
| ATRC | ▼ Sell | Gift | 10,000 | $0 | 8/8/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 822 | $21K | 6/30/2025 | View on chart |
| ATRC | ▼ Sell | Gift | 4,000 | $0 | 3/10/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 50,335 | $0 | 3/1/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 50,907 | $0 | 3/1/2025 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 43,926 | $1.7M | 3/1/2025 | View on chart |
| ATRC | ▼ Sell | Gift | 3,000 | $0 | 8/14/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 707 | $14K | 6/28/2024 | View on chart |
| ATRC | ▼ Sell | Gift | 2,000 | $0 | 3/14/2024 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 47,824 | $1.7M | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 50,854 | $0 | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 69,142 | $0 | 3/1/2024 | View on chart |
| ATRC | ▼ Sell | Gift | 10,000 | $0 | 11/27/2023 | View on chart |
| ATRC | ▼ Sell | Gift | 1,250 | $0 | 8/4/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 557 | $21K | 6/30/2023 | View on chart |
| ATRC | ▼ Sell | Gift | 1,000 | $0 | 5/31/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 69,234 | $0 | 3/1/2023 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 45,470 | $1.8M | 3/1/2023 | View on chart |
| ATRC | ▼ Sell | Gift | 800 | $0 | 3/1/2023 | View on chart |
| ATRC | ▼ Sell | Gift | 800 | $0 | 3/1/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 45,993 | $0 | 3/1/2023 | View on chart |
| ATRC | ▼ Sell | Gift | 6,000 | $0 | 11/17/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 350 | $12K | 6/30/2022 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 43,167 | $3.0M | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 22,632 | $0 | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 67,109 | $0 | 3/1/2022 | View on chart |
| ATRC | ▼ Sell | Gift | 510 | $0 | 2/24/2022 | View on chart |
| ATRC | ▼ Sell | Gift | 510 | $0 | 2/24/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 141 | $8K | 12/31/2021 | View on chart |
| ATRC | ▼ Sell | Gift | 10,000 | $0 | 12/7/2021 | View on chart |
| ATRC | ▼ Sell | Gift | 345 | $0 | 11/12/2021 | View on chart |
| ATRC | ▼ Sell | Gift | 345 | $0 | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BTIG raises AtriCure price target to $63
BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.
BTIG raises AtriCure price target to $63. BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.